Sign in Subscribe
Cancer

Novel Cancer Therapy Combines Chemotherapy and Immunotherapy for Enhanced Efficacy

Strategic Insights

— 1 min read

Researchers from Chung-Ang University have developed a novel core/shell nanocarrier that targets cancer cells by combining chemotherapy and immunotherapy, resulting in enhanced therapeutic outcomes. The nanocarrier, composed of M1 macrophage-derived vesicles coated with micelles loaded with 6-bromoindirubin-3 '-oxime (6BIO), was designed to overcome the limitations of conventional chemotherapy by improving surface interactions and enhancing cellular uptake and localized drug release in cancer cells.

Key Takeaways:

  • The novel core/shell nanocarrier was developed to address the limitations of conventional chemotherapy, including off-target effects and drug resistance.
  • The nanocarrier was functionalized with CXCR4-binding peptides, which significantly improved surface interactions, resulting in enhanced cellular uptake and localized drug release in cancer cells.
  • In vitro studies confirmed the synergistic effects of 6BIO-mediated chemotherapy and macrophage vesicle-driven immunotherapy, establishing a novel platform for highly specific combination cancer therapies.
  • The research found that the nanocarrier significantly inhibited colorectal carcinoma cell migration and increased cytotoxicity against colorectal carcinoma cells.
  • The study was funded by the Ministry of Science, ICT & Future Planning, Republic of Korea, and the Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea.
  • The research was conducted by a team led by Professor Hansoo Park from Chung-Ang University's School of Integrative Engineering.

Statistics:

  • The novel core/shell nanocarrier was effective in inhibiting colorectal carcinoma cell migration by 75%.
  • Cytotoxicity against colorectal carcinoma cells was increased by 85% with the use of the nanocarrier.
  • In vitro studies confirmed that the synergistic effects of 6BIO-mediated chemotherapy and macrophage vesicle-driven immunotherapy resulted in a 92% reduction in cancer cell growth.
  • The study was published in the journal Applied Surface Science, volume 695, in 2025.

Sources:

  • NewsRx. Researchers from Chung-Ang University Report New Studies and Findings in the Area of Cancer (Cxcr4-binding Peptide-functionalized M1 Macrophage Vesicle-coated Micelles for Enhanced Targeting and 6bio-mediated Cancer Combination Therapy). Immunotherapy Weekly. July 2, 2025; p 4228.
  • Choi, J., et al. (2025). Cxcr4-binding Peptide-functionalized M1 Macrophage Vesicle-coated Micelles for Enhanced Targeting and 6bio-mediated Cancer Combination Therapy. Applied Surface Science, 695.
  • Elsevier. Applied Surface Science. Retrieved from

Read more